Loading…
Japan's largest clinical laboratory testing operator, running diagnostic tests for hospitals and clinics nationwide.
Japan's largest clinical laboratory testing operator, running diagnostic tests for hospitals and clinics nationwide.
Earns testing fees per sample from hospitals and clinics that send blood and tissue to its laboratories, plus sales of diagnostic reagents through Fujirebio, which it owns, including tests used in Alzheimer's diagnosis. Japan's national fee schedule sets test prices, so volume and efficiency matter more than pricing.
In one line: Japan's Quest Diagnostics / LabCorp.
Moat: narrow (scale, installed base, regulatory licence). Largest lab-testing network in Japan gives scale economics that smaller labs cannot match.
Headquarters: Tokyo, Japan · Founded: 1970 · Employees: 5,157
Size H.U.Group (4544.T) is a Japan Health Care company (Medical/Nursing Services) with a market value of $1.35B, the 610th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,856 on 6 Nov 2026.
Performance Over six months the shares gained 23.9%, against +20.6% for the median peer and +1.8% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 1.5% over the last twelve months (peer median +7.9%); the operating margin is 2.4% (peer median 6.2%).
Valuation It trades at 41.0× forward earnings against a peer median of 25.1× (5th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.2 points below its cost of capital (5.0% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥249B | ¥247B | ¥243B | ¥237B | ¥261B |
| Revenue growth | — | +2% | +3% | -9% | — |
| Gross profit | ¥71.5B | ¥70.8B | ¥61.3B | ¥57.3B | ¥84.5B |
| EBITDA | ¥27.4B | ¥26.5B | ¥23.1B | ¥16.8B | ¥43.1B |
| Net income | ¥9.59B | ¥6.82B | ¥2.76B | -¥7.55B | ¥15.7B |
| Free cash flow | ¥21.2B | ¥19.2B | ¥20.9B | ¥4.18B | ¥18.3B |
| Capital expenditure | ¥4.86B | ¥4.86B | ¥10.3B | ¥17.6B | ¥21.7B |
| Total debt | ¥60.3B | ¥74.3B | ¥86.7B | ¥81.9B | ¥77.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| H.U.Group 4544.T | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% |
| Quest Diagnostics DGX | $28.1B | +36% | +9% | 15% | 22.0× | 6.4% |
| Labcorp LH | $29.8B | +45% | +6% | 11% | 19.0× | 13.9% |
| BML 4694.T | $887M | -2% | +4% | 7% | 18.6× | -9.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4544.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.9% | +4.8% | 8th highest of 21 |
| 6-month return | +23.9% | +20.6% | 9th highest of 21 |
| Distance from 52-week high | -5.3% | -17.1% | 3rd highest of 21 |
| Revenue growth (TTM) | +1.5% | +7.9% | 8th lowest of 21 |
| Operating margin | 2.4% | 6.2% | 6th lowest of 21 |
| Forward P/E | 41.0× | 25.1× | 5th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 10.1% | 15.7% | 7th least demanding of 17 |
| Growth delivered (Del g) | +2.1% | +13.7% | 2nd lowest of 17 |
| Hurdle (Req g minus delivered) | +8.0 pp | +1.0 pp | 7th most demanding of 17 |
| ROIC minus cost of capital | -2.2 pp | -3.7 pp | 8th highest of 20 |
| EV / EBITDA | 8.3× | 16.8× | 6th cheapest of 17 |
| Net debt / EBITDA | 0.6× | 1.3× | 7th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |